IM Cannabis actively evaluating opportunities to expand operations into U.S.

IM Cannabis (IMCC) announced that it is actively evaluating certain strategic opportunities to expand its operations into the United States cannabis market. This initiative follows President Donald Trump’s executive order signed on December 18, 2025, which directs the Attorney General to expedite the rescheduling of marijuana from Schedule I to Schedule III under the Controlled Substances Act, recognizing its medical benefits while maintaining federal oversight. To advance its U.S. entry strategy and assess potential divestitures of its businesses in Germany and Israel, the Company has engaged SSC Advisors to act as its financial advisors.